Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
BMJ Case Rep ; 17(1)2024 Jan 18.
Article in English | MEDLINE | ID: mdl-38238162

ABSTRACT

Shiga toxin (Stx)-producing Escherichia coli-mediated haemolytic uraemic syndrome is a primary thrombotic microangiopathy, typified by the development of microangiopathic haemolytic anaemia, thrombocytopaenia and acute renal failure. It is a leading cause of acute renal failure in paediatrics, with a second peak in prevalence in adults over the age of 60. Presentations of Stx-producing E. coli-mediated haemolytic uraemic syndrome in young adults are rare. We present the case of a previously well female in her early 30s presenting with Stx-producing E. coli-mediated haemolytic uraemic syndrome with severe renal and neurological manifestations. Eculizumab was administered due to the severity of presentation and disease trajectory refractory to initial supportive therapy. A significant clinical and biochemical improvement was observed following eculizumab.


Subject(s)
Acute Kidney Injury , Antibodies, Monoclonal, Humanized , Escherichia coli Infections , Hemolytic-Uremic Syndrome , Shiga-Toxigenic Escherichia coli , Humans , Child , Female , Shiga Toxin/therapeutic use , Hemolytic-Uremic Syndrome/drug therapy , Escherichia coli Infections/complications , Escherichia coli Infections/drug therapy , Acute Kidney Injury/drug therapy , Acute Kidney Injury/etiology
SELECTION OF CITATIONS
SEARCH DETAIL